• 1
    Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA. 1995; 273: 577-585.
  • 2
    Tilanus-Linthorst MM, Kriege M, Boetes C, et al. Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer. 2005; 41: 1620-1627.
  • 3
    Litton JL, Westin SN, Ready K, et al. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009; 115: 1598-1604.
  • 4
    Duffy SW, Tabar L, Vitak B, et al. The Swedish Two-County Trial of mammographic screening: cluster randomisation and end point evaluation. Ann Oncol. 2003; 14: 1196-1198.
  • 5
    Peer PG, Verbeek AL, Straatman H, et al. Age-specific sensitivities of mammographic screening for breast cancer. Breast Cancer Res Treat. 1996; 38: 153-160.
  • 6
    Kerlikowske K, Grady D, Rubin SM, et al. Efficacy of screening mammography: a meta-analysis. JAMA. 1995; 273: 149-154.
  • 7
    de Koning HJ, Boer R, Warmerdam PG, et al. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst. 1995; 87: 1217-1223.
  • 8
    van Gils CH, Otten JD, Verbeek AL, et al. Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, the Netherlands. J Epidemiol Commun Health. 1998; 52: 267-271.
  • 9
    Meyer JE, Kopans DB, Oot R, et al. Breast cancer visualized by mammography in patients under 35. Radiology. 1983; 147: 93-94.
  • 10
    Swedish Cancer Society, Swedish National Board of Health and Welfare. Breast-cancer screening with mammography in women aged 40-49 years. Int J Cancer. 1996; 68: 693-699.
  • 11
    Hendrick RE, Smith RA, Rutledge JH III, Smart CR. Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr. 1997; 22: 87-92.
  • 12
    Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women with high familial risk for breast cancer. J Clin Oncol. 2005; 23: 8469-8476.
  • 13
    Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutations carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004; 292: 1317-1325.
  • 14
    Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004; 351: 427-437.
  • 15
    Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005; 365: 1769-1778.
  • 16
    Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk of breast cancer with mammography and magnetic resonance imaging. Cancer. 2005; 103: 1898-1905.
  • 17
    Podo F, Sardanelli F, Canese R, et al. The Italian multicentre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res. 2002; 21: 115-124.
  • 18
    Ikeda DM, Hylton NM, Kuhl CK, et al. BI-RADS: Magnetic Resonance Imaging. In: D'Orsi CJ, Mendelson, EB, Ikeda DM, et al, eds. Breast Imaging Reporting and Data System: ACR BI-RADS—Breast Imaging Atlas. 1st ed. Reston, VA: American College of Radiology; 2003: 1-2.
  • 19
    Weinstein SP, Localio AR, Conant EF. Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol. 2009; 20: 6124-6128.
  • 20
    Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008; 299: 2151-5163.
  • 21
    Gilbert FJ, Warren RM, Kwan-Lim G, et al. Cancers in BRCA1 and BRCA2 and in women at high risk for breast cancer: MR imaging and mammographic features. Radiology. 2009; 252: 358-369.
  • 22
    Lehman CD, Isaacs C, Schnall MD, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology. 2007; 244: 381-388.
  • 23
    Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004; 22: 2328-2335.
  • 24
    US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 151: 716-726, W236.
  • 25
    Kerlikowske K, Cook AJ, Buist DS, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol. 2010; 28: 3830-3837.
  • 26
    McCormack V, Dos Santos S. Breast density and parenchymal patterns as markers of breast cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1159-1169.
  • 27
    Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009; 27: 5887-5892.